Literature DB >> 30586508

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

.   

Abstract

Entities:  

Year:  2018        PMID： 30586508     DOI： 10.1056/NEJMx180043

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Effect of Bevacizumab on a Human Breast Cancer Model that Exhibited Palbociclib-resistance by RB Knockout.

Authors:  Nobuyuki Ishikura; Masamichi Sugimoto; Keigo Yorozu; Mitsue Kurasawa; Daiko Wakita; Osamu Kondoh
Journal:  Cancer Diagn Progn       Date:  2022-09-03

Review 2.  Highlights in Resistance Mechanism Pathways for Combination Therapy.

Authors:  João M A Delou; Alana S O Souza; Leonel C M Souza; Helena L Borges
Journal:  Cells       Date:  2019-08-30       Impact factor: 6.600

3.  Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.

Authors:  Mariya Rozenblit; Sophia Mun; Pamela Soulos; Kerin Adelson; Lajos Pusztai; Sarah Mougalian
Journal:  Breast Cancer Res       Date:  2021-01-29       Impact factor: 6.466
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.